Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Cosmegen
Actinomycin D, also known as dactinomycin, is an antineoplastic antibiotic derived from *Streptomyces* species. It exerts its cytotoxic effect by intercalating into DNA, thereby inhibiting RNA and DNA synthesis. This potent action makes it effective against certain types of cancer but also contributes to significant side effects. It's particularly used in pediatric oncology and for specific tumor types like Wilms' tumor and rhabdomyosarcoma.
Used to treat Wilms' tumor, Ewing's sarcoma, rhabdomyosarcoma, gestational trophoblastic neoplasia, and other specific cancers.
Actinomycin D is a potent cytotoxic agent. Extravasation can result in severe tissue damage, including necrosis. Monitor closely for signs of extravasation and administer through a freely flowing intravenous line. Myelosuppression is common and can be severe.
Outcome:
Increased bleeding risk
Mechanism:
Enhanced anticoagulant effect
Outcome:
Increased risk of bleeding
Mechanism:
Additive effects on platelet function
Outcome:
Decreased absorption
Mechanism:
Chelation
Most likely new formulation: Nanoformulation for improved delivery (Year: 2028, 30% confidence)
Based on current clinical trial activity, there is a low (5%) likelihood of a new indication being approved within the next 5 years.
Antineoplastic, Antibiotic
Actinomycin